Page last updated: 2024-09-02

fingolimod hydrochloride and fumarates

fingolimod hydrochloride has been researched along with fumarates in 24 studies

Compound Research Comparison

Studies (fingolimod hydrochloride)	Trials (fingolimod hydrochloride)	Recent Studies (post-2010) (fingolimod hydrochloride)	Studies (fumarates)	Trials (fumarates)	Recent Studies (post-2010) (fumarates)
2,771	157	2,062	4,655	342	1,823

Research

Studies (24)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (16.67)	29.6817
2010's	20 (83.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Burton, JM; O'Connor, P	1
Borriello, G; Cefaro, LA; Gasperini, C; Pozzilli, C; Prosperini, L; Tosto, G	1
Hartung, HP; Kieseier, BC; Stüve, O; Wiendl, H	1
Gasperini, C; Ruggieri, S	1
Fontoura, P; Garren, H	1
Gold, R	1
Jadidi-Niaragh, F; Mirshafiey, A	1
Csépány, T	1
Killestein, J; Polman, CH; Rudick, RA	1
Graham-Rowe, D	1
Ais-Larisgoitia, A; de Lorenzo-Pinto, A; Rodríguez-González, CG	1
Fox, RJ	1
Agarwal, S; Deniz, B; Fox, RJ; Havrdova, E; Hutchinson, M; Kurukulasuriya, NC; Sarda, SP; Siddiqui, MK; Taneja, A	1
Alwan, S; Dahlgren, L; Lu, E; Sadovnick, AD; Synnes, A; Tremlett, H; Wang, BW	1
Sorensen, PS	1
di Nuzzo, L; Nasca, C; Nicoletti, F; Orlando, R	1
Lovett-Racke, AE; Racke, MK; Yang, Y	1
Bridel, C; Lalive, PH	1
McDonald, EA; Sedal, L; Wilson, IB	1
Hay, JW; Niu, X; Zhang, X	1
Moses, H	1
Thomas, RH; Wakefield, RA	1
Carreón-Guarnizo, E; Hernández-Clares, R; Meca-Lallana, JE	1
Hahn, JN; Kaushik, DK; Mishra, MK; Silva, C; Wang, J; Yong, VW	1

Reviews

18 review(s) available for fingolimod hydrochloride and fumarates

Article	Year
Novel oral agents for multiple sclerosis. Current neurology and neuroscience reports, 2007, Volume: 7, Issue:3 Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine	2007
Emerging oral drugs for multiple sclerosis. Expert opinion on emerging drugs, 2008, Volume: 13, Issue:3 Topics: Administration, Oral; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2008
New oral drugs for multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2009, Volume: 30 Suppl 2 Topics: Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2009
Multiple sclerosis therapies: molecular mechanisms and future. Results and problems in cell differentiation, 2010, Volume: 51 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Cladribine; Crotonates; Daclizumab; Dimethyl Fumarate; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Immunotherapy; Mice; Multiple Sclerosis; Myelin Basic Protein; Nitriles; Peptide Fragments; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Vaccines, DNA	2010
Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved. CNS drugs, 2011, Volume: 25, Issue:1 Topics: Administration, Oral; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2011
Therapeutic approach to multiple sclerosis by novel oral drug. Recent patents on inflammation & allergy drug discovery, 2011, Volume: 5, Issue:1 Topics: Administration, Oral; Cladribine; Crotonates; Diterpenes; Epoxy Compounds; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Multiple Sclerosis; Nitriles; Patents as Topic; Phenanthrenes; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2011
[Current treatment of multiple sclerosis]. Lege artis medicinae : uj magyar orvosi hirmondo, 2011, Volume: 21, Issue:2 Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cladribine; Dimethyl Fumarate; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Propylene Glycols; Quinolones; Sphingosine; Treatment Outcome	2011
Oral treatment for multiple sclerosis. The Lancet. Neurology, 2011, Volume: 10, Issue:11 Topics: Administration, Oral; Cladribine; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2011
[Emerging therapies for multiple sclerosis]. Medicina clinica, 2013, Jan-19, Volume: 140, Issue:2 Topics: 4-Aminopyridine; Administration, Oral; Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Cladribine; Clinical Trials as Topic; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Middle Aged; Multicenter Studies as Topic; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Rituximab; Sphingosine; Toluidines; Young Adult	2013
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Current medical research and opinion, 2014, Volume: 30, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Randomized Controlled Trials as Topic; Recurrence; Sphingosine; Toluidines	2014
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS drugs, 2014, Volume: 28, Issue:2 Topics: Abnormalities, Drug-Induced; Administration, Oral; Animals; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Multiple Sclerosis; Nitriles; Pregnancy; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Toluidines	2014
New management algorithms in multiple sclerosis. Current opinion in neurology, 2014, Volume: 27, Issue:3 Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal, Humanized; Clinical Protocols; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines	2014
Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis. Drug design, development and therapy, 2014, Volume: 8 Topics: Administration, Oral; Animals; Blood-Brain Barrier; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immune System; Multiple Sclerosis; NF-E2-Related Factor 2; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2014
Is T-bet a potential therapeutic target in multiple sclerosis? Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2014, Volume: 34, Issue:8 Topics: Animals; Antibodies, Monoclonal, Humanized; Dimethyl Fumarate; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Immunotherapy; Molecular Targeted Therapy; Multiple Sclerosis; Natalizumab; Propylene Glycols; Sphingosine; T-Box Domain Proteins; Th17 Cells	2014
Update on multiple sclerosis treatments. Swiss medical weekly, 2014, Volume: 144 Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Daclizumab; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Sphingosine; Toluidines	2014
Current management of relapsing-remitting multiple sclerosis. Internal medicine journal, 2014, Volume: 44, Issue:10 Topics: Administration, Intravenous; Administration, Oral; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Administration Schedule; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Nitriles; Propylene Glycols; Risk Assessment; Sphingosine; Toluidines	2014
Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Jan-01, Volume: 72, Issue:1 Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Disease Progression; Drug Approval; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Sphingosine; Toluidines; United States; United States Food and Drug Administration	2015
[Oral treatments in multiple sclerosis]. Medicina clinica, 2014, Volume: 143 Suppl 3 Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2014

Other Studies

6 other study(ies) available for fingolimod hydrochloride and fumarates

Article	Year
The future of multiple sclerosis therapy. Pharmacological research, 2009, Volume: 60, Issue:4 Topics: Administration, Oral; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cladribine; Crotonates; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunologic Factors; Injections, Intravenous; Injections, Subcutaneous; Interferon-beta; Multiple Sclerosis; Nitriles; Propylene Glycols; Quinolones; Sphingosine; Toluidines	2009
Drugs: An injection of hope. Nature, 2012, Apr-12, Volume: 484, Issue:7393 Topics: Alemtuzumab; Animals; Antibodies, Monoclonal, Humanized; Cladribine; Clinical Trials, Phase III as Topic; Crotonates; Dimethyl Fumarate; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Inflammation; Multiple Sclerosis; Natalizumab; Nitriles; Propylene Glycols; Quinolones; Risk Assessment; Sphingosine; Toluidines; United States; United States Food and Drug Administration	2012
In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes. Multiple sclerosis (Houndmills, Basingstoke, England), 2013, Volume: 19, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Clinical Trials as Topic; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Glatiramer Acetate; Humans; Hydroxybutyrates; Immunologic Factors; Interferons; Multiple Sclerosis; Natalizumab; Nitriles; Peptides; Propylene Glycols; Sphingosine; Toluidines	2013
Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS drugs, 2015, Volume: 29, Issue:1 Topics: Adolescent; Adult; Cohort Studies; Cost-Benefit Analysis; Dimethyl Fumarate; Disability Evaluation; Female; Fingolimod Hydrochloride; Fumarates; Humans; Immunologic Factors; Injections, Intramuscular; Interferon beta-1a; Interferon-beta; Male; Markov Chains; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Propylene Glycols; Randomized Controlled Trials as Topic; Sphingosine; Young Adult	2015
Recognizing and overcoming potential barriers to oral medications for MS. The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10 Topics: Administration, Oral; Crotonates; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Multiple Sclerosis; Nitriles; Propylene Glycols; Sphingosine; Toluidines	2014
Impact of Minocycline on Extracellular Matrix Metalloproteinase Inducer, a Factor Implicated in Multiple Sclerosis Immunopathogenesis. Journal of immunology (Baltimore, Md. : 1950), 2016, 11-15, Volume: 197, Issue:10 Topics: Animals; Anti-Bacterial Agents; Basigin; Central Nervous System; Clinical Trials, Phase III as Topic; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Fingolimod Hydrochloride; Fumarates; Humans; Interferon-beta; Lymphocyte Activation; Maleates; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Minocycline; Monocytes; Multiple Sclerosis; T-Lymphocytes; Tissue Inhibitor of Metalloproteinase-1	2016